BiomX Ltd. logo

BiomX Ltd.

We are developing customized #phage therapies that target and destroy harmful microbiome bacteria in chronic diseases such as IBD and cancer BiomX is a microbiome drug discovery company developing customized phage therapies that target and destroy harmful bacteria in chronic diseases. BiomX therapeutic pipeline consists of products for the treatment of acne, Inflammatory Bowel Disease (IBD), cancer, and therapeutics that modulate the microbiome for improved performance of immuno-oncology drugs.

BiomX platforms use computational and synthetic biology and cutting-edge research from Profs. Rotem Sorek, Dr. Eran Elinav and Dr. Eran Segal of The Weizmann Institute of Science; and Prof. Timothy K. Lu, of The Massachusetts Institute of Technology. BiomX is located at FutuRx Bioincubator facility.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.biomx.com
Founded2015
Disease Focus
Development Stage
STOCK CODENon Listed
Address
7 Pinhas Sapir St. Floor 2, 7414002
Ziona
Israel
Email
Contact Number
+972 723942377

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/biomxbio” connections=”true” suffix=””]

BiomX has accumulated four key technologies that shape its platform: two for target identification, and two for designing phage therapies that can eliminate the targets. BiomX also has two discovery cancer programs   one for gastrointestinal cancers, the other for immuno-oncology indications   that attack two different mechanisms by which the microbiome fuels tumor growth. In the first, the bacteria are present in the tumor and help it survive, in the second, they impair antitumor immunity.

In May 2017, BiomX Raises $24 Mn in Series A Funding, led by OrbiMed, JJDC, Inc. and Takeda Ventures, Inc. with participation from Seventure Partners, MiraeAsset, SBI Japan-Israel Innovation Fund and other European investors.